DecisionView to Create Clinical Trial Enrollment Benchmarks

San Francisco, CA – June 16, 2011 – DecisionView Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced that a number of pharmaceutical industry leaders including GlaxoSmithKline and Roche have agreed to participate in the creation of a set of industry patient enrollment benchmarks based on real-world clinical performance data. Each of the initial sponsors will contribute their historical enrollment data, which will be anonymized, aggregated, and made available to all participants via DecisionView’s StudyOptimizer for use in benchmarking, planning and forecasting clinical trial enrollment.

“There is a huge demand for clinical performance data to inform and calibrate clinical trial planning,” said Alex Lancksweert, Director of Performance & Supplier Governance at GlaxoSmithKline. “Unfortunately, current solutions are not integrated directly into our processes or tools, making it difficult take advantage of them. We see a lot of value in leveraging the detailed enrollment performance data that already exists in StudyOptimizer to provide planning information at the point of need, in an accessible format.”

 “We fully support this effort to create the first industry-wide patient enrollment data set for benchmarking purposes,” said Henk de Wilde, Global Head Information Management for Clinical Operations at Roche. “Organizations like Roche already have large, existing internal data sets available, but this internal data doesn’t allow us to compare our performance to the rest of the market. And DecisionView is uniquely positioned to lead this initiative, since so many of the industry’s leading life science firms already have their enrollment data hosted on StudyOptimizer.”

Why An Enrollment Benchmarks Data Set?
There is significant demand for trusted clinical trial performance data across a number of different clinical operations processes, including patient enrollment, site selection, budgeting, and clinical supply. In particular, more accurate patient enrollment benchmark data promises to significantly reduce clinical trial delays and cost overruns. Traditional sources for this type of benchmark information include company internal study data, third party data sets, and survey-based benchmarks.  But capturing and maintaining this type of data over time can be challenging, for a number of reasons:

• lack of data granularity (e.g. ability to segment the data by patient population, inclusion/exclusion criteria, etc,),
• inconsistent data collection,
• lack of data breadth/scope/coverage across multiple therapeutic areas and geographic regions
• no integration with planning processes and tools,
• infrequent updates
• significant cost

Because of these challenges, a number of DecisionView’s customers asked the company to coordinate an effort to aggregate and share the clinical enrollment data that already exists in the StudyOptimizer product.

DecisionView Enrollment Benchmarks™
In response, DecisionView has announced a new product called DecisionView Enrollment Benchmarks, a set of metrics based on real-world clinical performance data aggregated from DecisionView customers. In order to access the data set, customers must agree to contribute their enrollment data, which will be aggregated and anonymized to ensure the confidentiality of sponsor studies. The breadth and depth of studies in the Enrollment Benchmarks data set will grow as participating sponsors complete additional studies, and as new contributors add their portfolios of completed trial data.

The benefits of DecisionView’s approach to aggregating enrollment benchmarks include:

• Trusted Data – because the data is collected through StudyOptimizer and has been mapped to their data definitions, sponsors understand how it is defined and gathered
• Planning Support – the rich set of clinical performance data informs and calibrates both initial clinical trial planning and trial rescue/recovery planning
• Just-In-Time Data - provides planning information at the point of need, in an easily-accessible format
• New Markets - provides benchmark information where sponsors have little or no prior experience – new indications or new countries
• Actionable - provides study teams, not just senior management, with a prospective capability to affect improved performance

ABOUT DECISIONVIEW
DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView’s flagship solution, StudyOptimizer, helps organizations optimize clinical trial enrollment by aggregating patient recruitment data from multiple sources and providing analytics, visualizations, and predictive scenario modeling that delivers unique and actionable insight. StudyOptimizer is used by 8 of the top 10 global pharmaceutical companies, and has been used on over 1,250 clinical studies with over 450,000 subjects enrolled in 13 different therapeutic areas across 91 different countries. Investors in the company include Granite Ventures and Aeris Capital. For additional information about DecisionView, go to http://www.decisionview.com or call 415-538-1800.

###